Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation
| Autor: | Saurabh Chhabra, Surbhi Sidana, Hemant S. Murthy, Amer Beitinjaneh, Anita D'Souza, Murali Janakiram, Vaibhav Agrawal, Rajshekhar Chakraborty, Saad Usmani, Binod Dhakal, Muzaffar H. Qazilbash, Raphael Fraser, Mahmoud Aljurf, Ricardo D. Parrondo, Shaji Kumar, Cindy Lee, Bhagirathbhai Dholaria, Noel Estrada-Merly, Larry D. Anderson, Minoo Battiwalla, Rahul Banerjee, Shahrukh K. Hashmi, Tamna Wangjam, Asad Bashey, Sergio Giralt, Lazaros J. Lekakis, Nina Shah |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Melphalan
Oncology endocrine system medicine.medical_specialty Cyclophosphamide Population Transplantation Autologous Article Dexamethasone Bortezomib Autologous stem-cell transplantation Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Immunology and Allergy Humans education Lenalidomide Multiple myeloma Transplantation education.field_of_study business.industry Hematopoietic Stem Cell Transplantation Cell Biology Hematology Induction Chemotherapy medicine.disease Molecular Medicine business Multiple Myeloma medicine.drug |
| Zdroj: | Transplant Cell Ther |
| Popis: | BACKGROUND: Bortezomib-based triplet regimens, specifically bortezomib, lenalidomide and dexamethasone (VRD) and bortezomib, cyclophosphamide and dexamethasone (VCD) are the two most common induction regimens used in transplant-eligible patients with NDMM, with conflicting data on comparative efficacy and outcomes in this population. OBJECTIVES: We compared long-term outcomes of multiple myeloma (MM) patients receiving VRD vs. VCD induction prior to autologous stem cell transplant (ASCT). STUDY DESIGN: Patients registered with Center for International Blood and Marrow Transplant Registry were included if they underwent ASCT for MM from 01/2013 to 12/2018 within 6 months of diagnosis, received VRD or VCD induction and achieved pre-transplant ≥ partial response. Of 1,135 patients, 914 received VRD and 221 received VCD. RESULTS: Patients receiving VCD were more likely to have renal impairment and ISS stage III disease and less likely to receive full dose melphalan (200 mg/m(2)) conditioning (69% vs 80%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|